Kala Bio, Inc. (NASDAQ:KALA) and Virotek Inc. have finalised an exclusive distribution and reseller agreement covering Virotek’s ophthalmology genomic testing and screening programme in the United States.
Under the agreement, which took effect on September 4, 2026, Kala will serve as the sole U.S. distributor of the programme and will have the right to market, promote, distribute and resell Virotek’s ophthalmology genetic testing services.
The agreement has an initial one-year term, with continued exclusivity dependent on Kala achieving agreed commercial milestones. It follows a non-binding letter of intent announced on September 1, 2026.
Companies Agree Profit-Sharing Structure
Virotek will remain responsible for the programme’s infrastructure, supply of testing kits, specimen processing and clinical reporting. The company will also provide training and supporting materials to Kala’s channel partners.
The companies have agreed to a profit-sharing arrangement that will take effect after Virotek recovers its programme costs. No additional financial terms were disclosed.
The agreement also gives Kala a right of first refusal covering certain ophthalmology products and services that Virotek may seek to sell or license to third parties.
Kala and Virotek have also established a framework under which they may mutually agree to expand their relationship into areas including oncology, preventive health, telehealth and white-label distribution.
Kala Provides No Revenue Forecast From Agreement
Third-party market research cited in the companies’ release valued the U.S. genetic testing market at approximately $5.7 billion in 2025 and projected it to reach approximately $6.9 billion in 2026.
Kala said it has not established any revenue projections associated with the distribution agreement.
“This agreement grants Kala exclusive U.S. rights to a commercially active genomic testing program in ophthalmology, a field in which Kala has operated for more than a decade,” said Avi Minkowitz, Chief Executive Officer of Kala.
Dr. Saeid Babaei, Chairman and Chief Executive Officer of Virotek, said the partnership provides the ophthalmology programme with access to eye care practices, telehealth channels and patients across the United States.